Moreover O
, O
all O
adenosine B
receptor O
agonists O
: O
2 B
- I
p I
- I
( I
2 I
- I
carboxyethyl I
) I
phenethylamino I
- I
5 I
' I
- I
N I
- I
ethylcarboxamidoadenosine I
( O
CGS B
21680 I
) O
, O
A2A O
receptor O
agonist O
, O
N6 B
- I
cyclopentyladenosine I
( O
CPA B
) O
, O
A1 O
receptor O
agonist O
, O
and O
5 B
' I
- I
N I
- I
ethylcarboxamidoadenosine I
( O
NECA B
) O
, O
A2 O
/ O
A1 O
receptor O
agonist O
significantly O
and O
dose O
- O
dependently O
decreased O
cocaine B
- O
induced O
locomotor O
activity O
. O

Added O
in O
vitro O
to O
rat O
cortical O
membrane O
preparation O
, O
abecarnil B
increased O
[ O
3H O
] O
GABA B
binding O
, O
enhanced O
muscimol B
- O
stimulated O
36Cl O
- O
uptake O
and O
reduced O
the O
binding O
of O
t B
- I
[ I
35S I
] I
butylbicyclophosphorothionate I
( O
[ B
35S I
] I
TBPS I
) O
. O

Safety O
and O
compliance O
with O
once O
- O
daily O
niacin B
extended I
- I
release I
/ I
lovastatin I
as O
initial O
therapy O
in O
the O
Impact O
of O
Medical O
Subspecialty O
on O
Patient O
Compliance O
to O
Treatment O
( O
IMPACT O
) O
study O
. O

Niacin B
extended I
- I
release I
/ I
lovastatin I
is O
a O
new O
combination O
product O
approved O
for O
treatment O
of O
primary O
hypercholesterolemia O
and O
mixed O
dyslipidemia O
. O

This O
open O
- O
labeled O
, O
multicenter O
study O
evaluated O
the O
safety O
of O
bedtime O
niacin B
extended I
- I
release I
/ I
lovastatin I
when O
dosed O
as O
initial O
therapy O
and O
patient O
compliance O
to O
treatment O
in O
various O
clinical O
practice O
settings O
. O

Patients O
also O
received O
dietary O
counseling O
, O
educational O
materials O
, O
and O
reminders O
to O
call O
a O
toll O
- O
free O
number O
that O
provided O
further O
education O
about O
dyslipidemia O
and O
niacin B
extended I
- I
release I
/ I
lovastatin I
. O

Compliance O
to O
niacin B
extended I
- I
release I
/ I
lovastatin I
was O
77 O
% O
, O
with O
3 O
, O
245 O
patients O
completing O
the O
study O
. O

Niacin B
extended I
- I
release I
/ I
lovastatin I
1 O
, O
000 O
/ O
40 O
mg O
, O
dosed O
as O
initial O
therapy O
, O
was O
associated O
with O
good O
compliance O
and O
safety O
and O
had O
very O
low O
incidences O
of O
increased O
liver O
and O
muscle O
enzymes O
. O

Cardioprotective O
effect O
of O
ethanolic B
extract I
of I
Terminalia I
chebula I
fruits I
( O
500 O
mg O
/ O
kg O
body O
wt O
) O
was O
examined O
in O
isoproterenol B
( O
200 O
mg O
/ O
kg O
body O
wt O
) O
induced O
myocardial O
damage O
in O
rats O
. O

Vasodilation O
of O
large O
and O
small O
coronary O
vessels O
and O
hypotension O
induced O
by O
cromakalim B
and O
pinacidil B
were O
not O
affected O
by O
prior O
combined O
beta B
adrenergic I
and I
muscarinic I
receptors I
blockade I
but O
drug O
- O
induced O
tachycardia O
was O
abolished O
. O

Thrombotic O
complications O
in O
acute O
promyelocytic O
leukemia O
during O
all B
- I
trans I
- I
retinoic I
acid I
therapy O
. O

A O
case O
of O
acute O
renal O
failure O
, O
due O
to O
occlusion O
of O
renal O
vessels O
in O
a O
patient O
with O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
treated O
with O
all B
- I
trans I
- I
retinoic I
acid I
( O
ATRA B
) O
and O
tranexamic B
acid I
has O
been O
described O
recently O
. O

